In gene therapy race, bluebird leads Vertex in activating treatment centers but trails in patient starts

Five months out from their twin FDA approvals in sickle cell disease (SCD), who’s winning the race to treat patients with their respective gene therapies—bluebird bio or partners Vertex Pharmaceuticals and CRISPR Therapeutics?

It’s not an easy question to answer.